MedTrace Logo

Phase I Study in Patients With Solid Tumours

NCT00496028 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2010-09-22

No results posted yet for this study

Summary

This study will comprise 2 parts, a dose escalation phase and a dose expansion phase. The 2 phases are part of a single study and described by this single protocol. Patients entered into the dose escalation phase will not be entered into the expansion phase. All subjects must be suitable for treatment with either carboplatin and/or paclitaxel.

Conditions

  • Neoplasms

Interventions

DRUG

AZD0530

oral tablet

DRUG

Carboplatin

intravenous infusion

DRUG

Paclitaxel

intravenous infusion

Sponsors & Collaborators

Principal Investigators

  • Steinar Aamdal, MD · Radium Hospital, Norway

  • Mary Stuart, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2010-01-31
Completion
2010-03-31

Countries

  • France
  • Netherlands
  • Norway
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00496028 on ClinicalTrials.gov